ABIVAX: Abivax Phase 2a Study Results of Obefazimod in Rheumatoid Arthritis Published in the Journal Annals of the Rheumatic Diseases and Selected for Presentation at EULAR 2022

Phase 2a safety and efficacy study results of obefazimod (ABX464) in patients with rheumatoid arthritis (RA) published in the renowned and peer-reviewed journal "Annals of the Rheumatic Diseases (ARD)"

Related Keywords

United Kingdom ,United States ,Hungary ,Paris ,France General ,France ,Poland ,Belgium ,Regina Jehle ,Enregistrement Universel ,Ghislaine Gasparetto ,Paul Emery ,Jeanene Timberlake ,Ligia Vela Reid ,Claire Daien ,Anne Hennecke ,Hartmutj Ehrlich ,Mc Services ,European Congress ,Leeds Teaching Hospitals ,American College Of Rheumatology ,Rooney Partners ,University Hospital At Montpellier ,Leeds Musculoskeletal Biomedical Research Centre ,Leeds Institute Of Rheumatic ,Euronext ,Relations Investors Europe ,Rheumatic Diseases ,Annual European Congress ,Euronext Paris ,University Hospital ,Versus Arthritis Professor ,Leeds Teaching Hospitals Trust ,Leeds Institute ,Musculoskeletal Medicine ,United States Adopted Names ,French Autorit ,Des March ,Disease Activity Score ,American College ,Abivax ,Hase ,Study ,Results ,Obefazimod ,Rheumatoid ,Arthritis ,Published ,Journal ,Annals ,Rheumatic ,Diseases ,Elected ,Presentation ,Wular ,022 ,